Results 151 to 160 of about 549,867 (276)

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Through Mintzberg’s glasses: a fresh look at the organization of ministries of health

Bulletin of the World Health Organization, 2000
In 1987, district health care policies were officially adopted by a majority of developing countries. Many operational problems constraining implementation of such policies have subsequently been identified, most of which are attributable to well-known ...
Jean-Pierre Unger, Jean Macq, François Bredo, Marleen Boelaert   +3 more
doaj  

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

Molecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodriguez‐Vida, Nuria Juanpere, Jihyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent W. Mouw, Aristotelis Bamias, Filipe L. F. Carvalho, Joaquim Bellmunt   +10 more
wiley   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Developing a Core Outcome Measurement Set for Adult ICU Patients, the CoreMS-ICU-A Protocol. [PDF]

Acta Anaesthesiol Scand
Kjær MN, Bruun CRL, Mortensen CB, Schandl A, Haines K, Hofsø K, Blokzijl F, Granholm A, Møller MH, Tøgern A, Rasmussen BS, Poulsen LM, Strøm T, Laerkner E, Brøchner AC, Haberlandt T, Bunzel AG, Herløv LS, Holm A, Sivapalan P, Estrup S, Cronhjort M, Laake JH, Pfortmueller CA, Ostermann M, Cole JM, Wise MP, Wludarczyk A, Szczeklik W, Jovaiša T, Cecconi M, Sigurdsson MI, Nalos M, Hästbacka J, Mäkinen M, Dye J, Hammond N, Litton E, Keus F, Myatra SN, Vijayaraghavan BKT, Yadav K, Venkatesh B, Egerod I, Larsen RF, Needham DM, Rose L, Connolly B, Spies C, Hodgson C, Munblit D, Gorst S, Perner A, Collet MO.   +53 more
europepmc   +1 more source

Management of hypertension in mental health patients in a primary care setting : an assessment of quality of care

, 2009
Includes summary.Includes bibliographical references (leaves 44-48).In his experience working in the Metro District Health Services Clinics of the Department of Western Cape, the researcher has encountered numerous cases of sub-standard quality of ...
Motsohi, Tsepo
core  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Family or caregiver outcomes after critical illness (FOCUS): a protocol for a core outcome set development study. [PDF]

BMJ Open
Brown C, Hartley P, Malyon A, Connolly B, Lone NI, McPeake J.   +5 more
europepmc   +1 more source

A stakeholder derived framework for safety assessment in the NHS case management programme [PDF]

Patient safety measurement methods are dominated by outcome measurement, reducing them to counts of harm or adverse events. Performance measurement recognises the limitations of the sole use of outcome indicators and proposes the use of measures ...
Jones, Sarahjane
core  

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source